Fundz

Phio Pharmaceuticals

Marlborough, Massachusetts, United States · Biotechnology, Healthcare, Health Care

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for spec

Key facts

Headquarters
Marlborough, Massachusetts, United States
Employees
5
Industries
Biotechnology, Healthcare, Health Care
Status
Public (PHIO)
Website
phiopharma.com
LinkedIn
Company page

Recent activity at Phio Pharmaceuticals

  • : SEC 8-K (5.02): On September 28, 2026, Phio Pharmaceuticals Corp. held its 2026 Annual Meeting of Stockholders via live webcast, during which stockholders approved an important amendment to the company's Long Term Incentive Plan. This amendment increased the number of shares of common stock available for issuance under the 2020 Plan by an additional 1,500,000 shares, bringing the total to 2,452,017 shares. The approval reflects the Board of Directors' recommendation to enhance the company's incentive structure and align it with shareholder interests. The Plan Amendment became effective immediately upon approval, highlighting a strategic move to incentivize and retain key personnel within the organization.
  • : SEC 8-K (8.01): On September 14, 2026, PHIO Pharmaceuticals Corp. announced a key development milestone for its drug PH-762, which includes the submission of materials to the FDA to support the next phase of clinical development targeting cutaneous cell carcinoma. The announcement also mentions a planned Phase 2b neoadjuvant study. This development may significantly impact the company's strategic direction and potential market presence in oncology treatments.
  • : SEC 8-K (5.02): On July 20, 2026, Phio Pharmaceuticals Corp. expanded its Board of Directors by appointing Dr. R. Todd Plott, M.D. as a new member, increasing the total number of board members to six. Dr. Plott brings over 30 years of experience in dermatology and innovation, previously serving on an FDA advisory committee. As part of his appointment, he will also join the Board’s Governance Committee and will be entering into the company's standard indemnification agreement, which provides certain protections to board members in legal matters.
  • : Phio Pharmaceuticals Corp. Secures $6.36 Million Through At The Market Offering
  • : SEC 8-K (1.01): On April 8, 2026, Phio Pharmaceuticals Corp. entered into a Material Definitive Agreement called the At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This agreement allows the Company to offer and sell shares of its common stock, totaling up to $6,360,000, through the Sales Agent. The transaction is registered under the Securities Act of 1933 using the Company’s shelf registration statement, which was effective as of July 1, 2024. This arrangement provides Phio Pharmaceuticals with a flexible method to raise capital by issuing shares as needed, which could significantly support its operational needs and growth strategies.
  • : Phio Pharmaceuticals Enters Manufacturing Services Agreement
  • : SEC 8-K (8.01): On March 30, 2026, Phio Pharmaceuticals Corp. announced it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply. This agreement is significant as it will enable the company to enhance its clinical supply capabilities, ensuring that their drug products are manufactured according to regulatory standards. The press release indicates that this partnership is essential for supporting upcoming clinical trials, reflecting the company's commitment to advancing its therapeutic candidates. The strategic implications include increased operational capacity and potentially faster timelines for bringing products to market.
  • : SEC 8-K (8.01): On February 10, 2026, PHIO Pharmaceuticals Corp. announced the formal conclusion of the Safety Medical Committee regarding its Phase 1b clinical trial of PH-762. The announcement included updates on the clinical trial's response rates, indicating progress in their ongoing drug development efforts. This press release, meant to inform shareholders and the market, outlines significant insights into the trial outcomes that could impact future strategic directions and investment considerations for the company. The press release is detailed in Exhibit 99.1 attached to this filing.
  • : SEC 8-K (8.01): On January 20, 2026, PHIO Pharmaceuticals Corp. reported key tumor response data from their intratumoral PH-762 dose escalation trial for cutaneous carcinoma. The findings indicated favorable safety and tolerability across all dose escalations. Notably, there was a 70% overall response rate for squamous cell carcinomas, with 10 out of 14 responders achieving a complete 100% clearance. This data is significant as it demonstrates the efficacy of PH-762, potentially impacting future treatment strategies for this type of carcinoma and enhancing the company's profile in the oncology sector.
  • : SEC 8-K (8.01): On December 23, 2025, Phio Pharmaceuticals Corp. announced that the Federal Drug Administration (FDA) has accepted its nonclinical protocol study design for the drug PH-762. This represents a significant advancement in their drug development program, with the toxicology study set to commence in the first quarter of 2026. This acceptance may enhance the company's research credibility and potential market readiness once the drug advances through the necessary regulatory processes.

Phio Pharmaceuticals funding history

DateRoundAmount
Apr 2026Post-IPO Equity$6.4M
Nov 2025Venture$1.4M
Aug 2025Seed$232K
Jan 2025Seed$153K
Jan 2025Seed$208K

Leadership

  • Curtis Lockshin, Chief Executive Officer and Director
  • Robert Bitterman, Director
  • Linda Mahoney, Director
  • Gerrit Dispersyn, Executive Officer, Director
  • Geert Cauwenbergh, Director
  • Robert Bitterman, Director
  • H Dorman, Director
  • Jonathan Freeman, Director
  • Curtis Lockshin, Director
  • Robert Ferrara, Director
  • Geert Cauwenbergh, Director
  • Robert Bitterman, Director

Verified email and direct lines for Phio Pharmaceuticals’s decision-makers are on Fundz. See plans

Phio Pharmaceuticals in the news

Companies similar to Phio Pharmaceuticals

About Phio Pharmaceuticals: questions and answers

What does Phio Pharmaceuticals do?

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for spec

Where is Phio Pharmaceuticals headquartered?

Phio Pharmaceuticals is headquartered in Marlborough, Massachusetts, United States.

How many employees does Phio Pharmaceuticals have?

Phio Pharmaceuticals has about 5 employees.

Has Phio Pharmaceuticals raised funding?

Yes. Fundz has recorded 5 funding events for Phio Pharmaceuticals. The most recent, Post-IPO Equity of $6.4M, was in Apr 2026.

Who leads Phio Pharmaceuticals?

Curtis Lockshin is a Chief Executive Officer and Director at Phio Pharmaceuticals.

What is the latest news on Phio Pharmaceuticals?

On Sep 28, 2026, SEC 8-K (5.02): On September 28, 2026, Phio Pharmaceuticals Corp. held its 2026 Annual Meeting of Stockholders via live webcast, during which stockholders approved an important amendment to the company's Long Term Incentive Plan. This amendment increased the number of shares of common stock availabl

Is Phio Pharmaceuticals a public company?

Yes. Phio Pharmaceuticals is publicly traded under the ticker PHIO.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Phio Pharmaceuticals across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.